Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Change in Account Payables: 2023-2025

Historic Change in Account Payables for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$2.3 million.

  • NewAmsterdam Pharma Co N.V's Change in Account Payables fell 219.11% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 214.73%. This contributed to the annual value of -$12.9 million for FY2024, which is 355.38% down from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Change in Account Payables stood at -$2.3 million, which was down 480.31% from -$391,000 recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Change in Account Payables ranged from a high of $12.9 million in Q4 2023 and a low of -$9.2 million during Q3 2023.
  • Moreover, its 3-year median value for Change in Account Payables was -$2.3 million (2025), whereas its average is -$753,364.
  • Data for NewAmsterdam Pharma Co N.V's Change in Account Payables shows a peak YoY increase of 127.08% (in 2025) and a maximum YoY decrease of 219.11% (in 2025) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Change in Account Payables (Quarterly) stood at $12.9 million in 2023, then plummeted by 124.79% to -$3.2 million in 2024, then crashed by 219.11% to -$2.3 million in 2025.
  • Its Change in Account Payables was -$2.3 million in Q3 2025, compared to -$391,000 in Q2 2025 and $2.3 million in Q1 2025.